Acquired hemophilia develops in patients with no previous history. In the U.S. the disorder affects approximately 2.1 individuals per 1,000,000 per year, whereas in the U.K. acquired hemophilia occurs in 1.4 individuals per 1,000,000 per year. It is also opined that several patients may go misdiagnosed or undiagnosed thus making the exact prevalence difficult to determine. Although acquired hemophilia predominantly occurs at an advanced age, it may occur in individuals of any age. The incidence of acquired hemophilia advances with age and affects individuals between 60 to 40 years of age. A slight increase in incidence occurs in pregnant females between the ages of 20 to 40. In addition, acquired hemophilia affects individuals across all ethnic groups worldwide. A majority of acquired hemophilia cases involve deficiency of Factor VIII (AH A). A few cases report a deficiency of Factor IX (AH B). Rare cases of acquired hemophilia involving other clotting factors have been reported. The acquired hemophilia treatment market is anticipated to grow at a CAGR of 3.25% during the forecast period of 2023-2031.
Access the Complete Report with TOC at https://www.acutemarketreports.com/report/acquired-hemophilia-treatment-market
Around 70 to 80% of hemophilia patients suffer from severe hemophilia A, is associated with severe bleeding disorders. Therefore, the majority of products available in the market target patients with type A hemophilia. However, type B is anticipated to be the fastest-growing segment over the forecast period due to strong pipeline products targeting the treatment of type B hemophilia.
Prophylaxis treatment is considered a standard of care to prevent joint bleeding and chronic arthropathy in patients with severe hemophilia. Therefore, the prophylaxis treatment dominates the market. Many research observations concluded that prophylaxis treatment for hemophilia was quite effective and slowed the progression of damage and reduced the annualized bleeding rates. However, On-demand treatment is expected to grow at a faster pace during the forecast period, due to convenience factor and is also cost effective mode of treatment.
After scrutiny of the global acquired hemophilia treatment market, the regional trends, market sizes, and the overall growth paired with the latest and anticipated events, North America is observed to be the most dominant regional market for acquired hemophilia treatment. However, Asia Pacific promises significant opportunities during the forecast period, growing at a highest CAGR of 5.97% from 2023-2031.
The global acquired hemophilia treatment market is observed as a diversified and competitive market comprising a large number of players. The spearheading market players include Roche, Sanofi, Pfizer, Baxter, Takeda, CSL Behring; Novo Nordisk A/S; and others. The major market participants implemented growth strategies such as partnerships, new product launches, and operational expansion to gain a competitive advantage. The top most strategy followed by top competitors includes trial announcements. Key companies such as Pfizer, F. Hoffman LA Roche, Sanofi, Genentech Inc and Novo Nordisk are actively involved in product trials placed for approvals.
KEY MARKET MOVEMENTS
